On 28 May 2026, the United Kingdom National Screening Committee delivered its long-awaited verdict on prostate cancer screening. After years of mounting public pressure, headline campaigns by charities and celebrities, and the quiet accumulation of evidence from some of the largest oncology trials ever run, the committee recommended a screening programme — but only for a vanishingly narrow cohort: men aged 45 to 61 who carry a BRCA2 gene variant and who also have a family history of breast, ovarian, pancreatic or prostate cancer. Everyone else, including Black British men with double the lifetime risk of their white counterparts, remains outside the tent.

The committee’s chief investigator on the recent TRANSFORM trial, Professor Hashim Ahmed of Imperial College London, put the rationale unsentimentally: “currently the harms unfortunately outweigh the benefits of population level screening for most high-risk groups and the population as a whole.” But in the same press response, Ahmed went further. He declared himself “deeply disappointed with the recommendation of the National Screening Committee, particularly in relation to black men who have double the risk of getting prostate cancer.” Professor Ros Eeles of the Institute of Cancer Research, who led the IMPACT study, was sharper still. Capping screening at 61 rather than 69, she warned, “misses 42 per cent of prostate cancers in those with a BRCA2 pathogenic alteration.”

In other words: the committee’s own clinical collaborators believe the recommendation is too cautious, too narrow, and indifferent to populations who urgently need a programme. It stands in revealing contrast to how Israel — a far smaller country, with fewer resources per capita and considerably more existential distractions — has quietly built one of the more humane and effective real-world approaches to detecting this disease.

The numbers tell the first half of the story. Prostate cancer is now the most commonly diagnosed cancer in the United Kingdom. Around 12,300 British men die of it every year, roughly 34 every day. Mortality rates are eleven per cent higher in the most deprived communities than in the wealthiest. Cancer Research UK projects 17,500 annual deaths by the late 2030s. Incidence has risen from 109 to 159 per 100,000 person-years between 2000 and 2021. This is not a........

© The Times of Israel (Blogs)